AtriCure (ATRC) Investor Day 2025 summary

Strategic vision and market expansion

• Focus on eradicating complex atrial fibrillation (AFib) and post-operative pain, targeting large, underpenetrated markets estimated at over $10 billion globally.

• Vision 2030 aims to set new standards of care, with a goal to reach $1 billion in revenue by the end of the decade, up from $465M in 2024.

• Leadership in surgical AFib treatment, emphasizing innovation with over 550 patents and recent product launches like EnCompass clamp and CryoSphere platforms.

• Expansion into pain management and extremity applications, leveraging clinical evidence and new devices to address unmet needs.

• Commitment to U.S.-based manufacturing for quality and supply chain resilience.

Clinical evidence, product innovation, and milestones

• Major investments in clinical trials such as LEAPS/LeAAPS and BoxX-NoAF, targeting both prophylactic and therapeutic interventions in cardiac surgery.

• LEAPS 3 trial demonstrated a 33% reduction in stroke risk for AFib patients with left atrial appendage management, influencing global guidelines.

• Continuous product innovation includes next-gen EnCompass clamp, AtriClip Flex-Mini, cryoSPHERE+ and MAX probes, Cryo XT for extremities, and a new PFA platform for epicardial use.

• Advancing reimbursement and guideline improvements to increase access and adoption of therapies.

• Focused on expanding indications for both AFib and pain management, with PMA studies underway for new applications.

Financial performance and guidance

• Achieved double-digit revenue growth and positive adjusted EBITDA in 2023 and 2024, with a 14–19% CAGR over the past four years.

• 2025 guidance reaffirmed, with targets of $750M+ revenue and 14% EBITDA margin by 2028, and $1B revenue with 20%+ EBITDA margin by 2030.

• Gross margin steady at ~75%, with robust free cash flow conversion anticipated by decade’s end.

• Growth drivers include expanded product portfolio, robust R&D investment (20% of revenue), and scalable manufacturing capacity.

• Margin expansion expected through SG&A leverage, new product scale, and moderate R&D as a percentage of revenue.